Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (191-200 of 239) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|February 27, 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancerRebecca C Arend, Bradley J Monk, Thomas J Herzog, et al.
The American Journal of Hospice & Palliative Care|May 25, 2019
Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)Gary B Deutsch, Jeremiah L Deneve, Mazin F Al-Kasspooles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyKristina W Thiel, Eric J Devor, Virginia L Filiaci, et al.
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Gynecologic Oncology|April 18, 2013
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancerIsrael Zighelboim, Jason D Wright, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcomeAndrew Berchuck, Edwin S Iversen, Jingqin Luo, et al.
Gynecologic Oncology|May 29, 2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancerCarol Aghajanian, Virginia Filiaci, Don S Dizon, et al.
Gynecologic Oncology|April 17, 2019
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapiesStéphanie L Gaillard, Kaitlyn J Andreano, Laurie M Gay, et al.
Gynecologic Oncology|August 27, 2023
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 womenIan S Hagemann, Wei Deng, Richard J Zaino, et al.
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
Pageof 24

Showing results (191-200 of 239) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|February 27, 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancerRebecca C Arend, Bradley J Monk, Thomas J Herzog, et al.
The American Journal of Hospice & Palliative Care|May 25, 2019
Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)Gary B Deutsch, Jeremiah L Deneve, Mazin F Al-Kasspooles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyKristina W Thiel, Eric J Devor, Virginia L Filiaci, et al.
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Gynecologic Oncology|April 18, 2013
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancerIsrael Zighelboim, Jason D Wright, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcomeAndrew Berchuck, Edwin S Iversen, Jingqin Luo, et al.
Gynecologic Oncology|May 29, 2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancerCarol Aghajanian, Virginia Filiaci, Don S Dizon, et al.
Gynecologic Oncology|April 17, 2019
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapiesStéphanie L Gaillard, Kaitlyn J Andreano, Laurie M Gay, et al.
Gynecologic Oncology|August 27, 2023
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 womenIan S Hagemann, Wei Deng, Richard J Zaino, et al.
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
Pageof 24